Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02443103 · ClinicalTrials.gov registry record · NA
Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis
A NA study, sponsored by Kathy Miller.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT02443103 is a NA study that was terminated before completion, run by Kathy Miller. The registered enrollment target is 4 participants.
The verdict
NCT02443103, a NA study, was terminated before completion, sponsored by Kathy Miller.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
This study will explore the biologic activity of guanabenz in reducing bone turn over in solid tumor patients with bone metastasis. If successful, this repurposing of an already, generic drug could benefit patients faster than manufacturing a novel expensive compound.
Interventions
- DRUG Guanabenz acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-05-07 |
| Est. Completion | 2016-06-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02443103
The ClinicalTrials.gov registry entry for NCT02443103 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kathy Miller, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Guanabenz acetate is the first listed.
NCT02443103 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02443103 about?
NCT02443103 is a clinical study titled "Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis". This study will explore the biologic activity of guanabenz in reducing bone turn over in solid tumor patients with bone metastasis. If successful, this repurposing of an already, generic drug could benefit patients faster than manufacturing a novel expensive compound.
What is the current status of trial NCT02443103?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2015-05-07. Estimated completion is 2016-06-08.
What interventions are being tested in trial NCT02443103?
The interventions under investigation include: Guanabenz acetate (DRUG).
Who is sponsoring clinical trial NCT02443103?
This trial is sponsored by Kathy Miller, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.